Log In
Print
BCIQ
Print
Print this Print this
 

AZD1775, MK-1775

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionWEE1 tyrosine kinase (WEE1) inhibitor
Molecular Target WEE1 tyrosine kinase (WEE1)
Mechanism of ActionKinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationOvarian cancer
Indication DetailsTreat epithelial ovarian cancer; Treat ovarian cancer
Regulatory Designation
Partner AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today